Flow cytometric analysis of CD 62P expression in patients with acute myocardial infarction.
Much attention has been paid to the role of platelets in the pathogenesis of heart diseases, e.g. ischaemic disease and myocardial infarction. During platelet activation changes appear both in the internal structure and in the membrane. The release reaction is associated with the appearance of CD 62P (P-selectin). The aim of the present study was evaluate CD 62P expression in patients with acute myocardial infarction according to the disease duration and the type of treatment. We study 29 patients with acute myocardial infarction (MI). The patients were divided into two groups: group A--15 patients treated with heparin and aspirin and group B--14 patients treated with streptokinase, heparin and aspirin. The control group consisted of 21 healthy subjects. We indicated that P-selectin expression is influenced by infarction duration and type of treatment. Our study demonstrates that thrombolytic therapy inhibits platelet activation. Patients receiving streptokinase showed lower CD 62P expression than those treated only with heparin and aspirin, both before and after platelet activation with thrombin.
Dymicka-Piekarska
V
V
Department of Clinical Laboratory Diagnostics, Institute of Laboratory Diagnostics, Medical Academy of Białystok.
Kemona
H
H
Mantur
M
M
Stogowski
A
A
Kemona-Chetnik
I
I
Bychowski
J
J
D001241:Aspirin / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D019007:P-Selectin / Q000097:blood*; D015539:Platelet Activation; D013300:Streptokinase / Q000627:therapeutic use
D015415:Biomarkers; D019007:P-Selectin; D006493:Heparin; D013300:Streptokinase; D001241:Aspirin